UK-US Trade Deals: Medicines Pact & Tech Sovereignty Row
New UK-US medicines agreement aims to boost NHS access to innovative drugs, but critics warn of eroded sovereignty in wider trade pacts with Trump. Explore the debate.
Category : Search result: pharmaceutical
AU$33m Pharma Payments to Doctors Raise Ethics Concerns
New data reveals over 6,500 Australian doctors received payments from drug firms. Experts warn this influences prescriptions, raising serious healthcare ethics questions. Read the full investigation.
UK-US Pharma Deal: NHS to Pay 25% More for New Drugs
A new UK-US deal doubling spending on US medicines raises NHS funding fears. Experts warn of a 'problematic precedent' that could impact Australia and global healthcare systems.
UK-US agree zero tariff deal on pharmaceuticals
The UK has secured a major three-year deal for zero US import tariffs on pharmaceuticals, safeguarding £5bn in annual exports and boosting life sciences investment. Read the full analysis.
UK-US zero-tariff pharma deal, NHS drug price rise
The UK and US have agreed a landmark deal maintaining zero tariffs on pharmaceuticals, while the NHS commits to a 25% net price increase for new medicines. Explore the details and implications.
US and UK agree zero-tariffs on pharmaceuticals
The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products, ensuring access to latest medical breakthroughs. Read the full details.
FDA Implements Stricter Vaccine Approval Protocols
US regulator FDA announces major overhaul of vaccine approval process following COVID-19 review. New protocols aim to strengthen public trust in immunisation programmes.
Novo Nordisk shares slide after Ozempic pill fails
Novo Nordisk shares slumped over 10% after its Ozempic pill failed to slow Alzheimer's progression in major trials. Read the latest on the pharmaceutical giant's market struggles.
UK Plans 25% NHS Drug Threshold Rise to End Standoff
UK ministers propose 25% increase in NHS drug cost-effectiveness thresholds to resolve investment row with pharmaceutical giants and boost life sciences sector.
NHS faces generic-only drug future warns AstraZeneca
The CEO of pharmaceutical giant AstraZeneca warns that UK patients may be limited to generic medicines unless the NHS increases what it pays for innovative new treatments, raising concerns about healthcare quality and medical research funding.
Novo Nordisk cuts forecasts again as drug demand slows
Danish pharmaceutical giant Novo Nordisk has cut its sales and profit forecasts for the second time in three months, sending shockwaves through the healthcare sector as demand for its blockbuster weight-loss drugs shows signs of slowing.
Big Pharma's Tax Breaks: Are We Getting NHS Value?
Exclusive analysis reveals pharmaceutical giants received massive tax incentives while NHS faces funding crisis. Experts demand transparency on whether these breaks are delivering promised benefits to UK healthcare.
Novo Nordisk Bids for Metsera, Challenging Pfizer's Offer
Danish pharmaceutical giant Novo Nordisk has entered a bidding war with Pfizer for obesity-focused biotech firm Metsera, potentially disrupting the US company's planned acquisition in a major power play for obesity treatment dominance.
UK Pharma Crisis: Patients Face Treatment Delays
A critical pricing dispute between the UK government and pharmaceutical companies threatens patient access to vital medicines, with industry leaders warning of treatment delays and reduced NHS access to new drugs.
GSK CEO warns UK drug pricing reforms threaten life sciences
Emma Walmsley warns Britain's life sciences industry faces 'existential threat' from proposed drug pricing reforms that could drive investment and research overseas.
Page 1 of 1